RCS - Zotefoams PLC - Exclusivity agreement with Design Blue Limited

ZotefoamsAnnouncement

19/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240419:nRSS2424La&default-theme=true

RNS Number : 2424L  Zotefoams PLC  19 April 2024

 

Zotefoams plc

("Zotefoams" or "Group")

 

Exclusivity agreement with personal protection experts Design Blue Limited

 

19 April 2024 - Zotefoams, a world leader in cellular materials, is pleased to
announce that it has entered into an exclusivity agreement with design and
technology company, Design Blue Limited ('DBL') in relation to a newly
launched foam material, developed in partnership with DBL, for
high-performance impact protection solutions for the defence and law
enforcement sectors.

Regarded as world leaders in impact protection, DBL designs and manufactures
high-performance, shock absorbing and ballistic solutions under the D3O and
Delta Three Oscar brand, producing solutions for global customers that include
the US Department of Defence, Harley Davidson, Fox and Adidas. As well as
being used by Formula 1 and NASCAR race teams, D3O materials can be found
throughout a wide range of categories including sports, electronics,
motorcycle, automotive, defence and law enforcement.

For the first time, Zotefoams' ZOTEK(®) NC, a lightweight high-performance,
nylon-based foam, will be designed into D3O's highly effective body armour and
ballistic helmet liner systems - offering high levels of impact protection at
very light weight.

David Stirling, Zotefoams Group CEO, comments, "We are delighted to announce
our partnership with DBL, who will harness the exceptional performance
benefits of Zotefoams' high-performance material to revolutionise personal
protection for those working in defence and law enforcement. This partnership
perfectly aligns with our purpose of creating optimal material solutions for
the benefit of society."

Stuart Sawyer, DBL CEO, comments, "This partnership enables D3O to take
another step towards our vision of saving lives. By combining D3O's strengths
of protecting people, with Zotefoams' unique technology, we are introducing a
new era of ultra-lightweight, environment-stable ballistic protection that
will re-define the industry standard of protection."

 

-ENDS-

Enquiries:

 

 Zotefoams plc                         +44 (0) 208 664 1600
 David Stirling, Group CEO

 Gary McGrath, Group CFO

 IFC Advisory (Financial PR & IR)      +44 (0) 203 934 6630
 Graham Herring

 Tim Metcalfe

 Zach Cohen

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology
delivering optimal material solutions for the benefit of society. Utilising a
variety of unique manufacturing processes, including environmentally friendly
nitrogen expansion for lightweight AZOTE(®) polyolefin and ZOTEK(®)
high-performance foams, Zotefoams sells to diverse markets worldwide.
Zotefoams uses its own cellular materials to manufacture T-FIT(®) advanced
insulation for demanding industrial markets. Zotefoams also owns and licenses
patented microcellular foam technology to reduce plastic use in extrusion
applications and for ReZorce(®) mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites
in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam
products manufacture and conversion), Massachusetts, USA and Stilling, Denmark
(microcellular foam technology) and Jiangsu Province, China (T-FIT).

www.zotefoams.com (http://www.zotefoams.com)

AZOTE(®), ZOTEK(®), ReZorce(®) and T-FIT(®) are registered trademarks of
Zotefoams plc.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEANLPFEDLEFA